Ross Firestone

Myeloma Paper of the Day, August 26th, Suggested by Robert Orlowski (@Myeloma_Doc) @RossFirestone @DrOlaLandgren @szusmani @LesokhinMD oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #Myeloma @CancerWorldmag

#Myeloma Paper of the Day: Immune-MRD status informs tumor-MRD outcome prognostication in myeloma pts on Len maintenance; T cell profiles enriched w/ activated cytotoxic effectors predict early relapse & quiescent/naïve T-cells predicting remission: pubmed.ncbi.nlm.nih.gov/40853874/. #mmsm

It was fun to work with @RossFirestone in writing this editorial for @BloodPortfolio #Blood "More than myeloma: the trouble with “normal” plasma cells", on the recent article from @nickbolli @matteoclaudio84 sciencedirect.com/science/articl… @MSKCancerCenter @MSK_DeptOfMed #mmsm

1/ 🚨New research alert! 🚨Our study in @BloodCancerJnl shows that high WEE1 expression is an independent predictor of poor survival in multiple myeloma (MM), with @RossFirestone, @MalinHultcrantz, @LarryNortonMD, @szusmani, and the rest of the @MSKCancerCenter team! 🧵👇

Therapy–mediated BCMA expression loss after belantamab or anti-BCMA chimeric antigen receptor T cells underlies teclistamab failure in RRMM. ow.ly/sarP50SM9ys #lymphoidneoplasia #immunobiologyandimmunotherapy #multiplemyeloma

Thanks to the investigators and to our patients for help with this work! 7/7

We also found that, at times of active disease, low or undetectable levels of soluble BCMA reported on expression loss, offering a noninvasive method to test BCMA expression in clinical practice settings 6/7

Our work with @szusmani and @DavidJChungMD at @MSKCancerCenter looking at antigen escape with BCMA-targeting therapies in #MMSM patients is now out in @BloodJournal authors.elsevier.com/a/1jUXn1UYwnDBZ 1/7

We also can't ignore that remote healthcare utilization is part of the patient experience. Portal messages and phone calls, while not as burdensome as in-person visits, are important signals of patient unease. #rUHI 6/6

Conclusion: We need to do a better job preparing patients for the expected complications of BsAb and CAR T therapies (both major and minor) to avoid unnecessary healthcare interactions and improve QoL, while still keeping patients safe. 5/6

Notably, unscheduled interactions rarely altered treatments plans, and patients almost always went home from in-person visits without care escalation. 4/6

In this study we looked at unscheduled healthcare interactions in MM patients receiving CAR T or BsAbs, with a focus on remote interactions. We found that healthcare utilization was high, even in patients responding well to treatment. 2/6

Remote and in-person healthcare utilization was higher in BsAb patients, seemingly due to an increased incidence of low-risk infections (URIs, etc). 3/6

Excited to see our manuscript on healthcare utilization in CAR T and bispecifics patients with #MMSM in press! This work was spearheaded by Anna Howard RN and @isabelconcepci MSN FNP-C. ashpublications.org/bloodadvances/… 1/6

Link to paper here! ashpublications.org/bloodadvances/…

Lots of work still to do (stay tuned!) but these findings, along with work from other groups, show that immune status may be critical for response to bispecifics like Tec  6/6

Happy to see my first research paper of fellowship is officially in press! So, of course, it’s time for my first ever tweet discussing observations in real-world #Teclistamab patients with #MMSM! (ashpublications.org/bloodadvances/…) A quick thread 1/6